September 2016
Features
Stem Cells for Retina: Where Are We Now?
A review of multiple trials pursuing a breakthrough in cell-based therapies for AMD and hereditary retinal disorders.
Diabetes Drugs In the Retina Practice
How glucose-lowering therapies can influence surgical planning.
Taking OCT Out To The Retinal Periphery
How ultra-widefield spectral domain optical coherence tomography gives us a new view of pathology.
Will OCT Angiography Replace FA?
A close look at how this emerging imaging modality compares with the gold standard.
Departments
Clinical Trial Closeup
Drugability of the Suprachoroidal Space
Phase II trial shows Clearside’s CLS-TA safe and effective in noninfectious uveitis.
Coding Commentary
Get Ready For ICD-10 Changes
The one-year reprieve ends October 1. Here’s what you can expect and how to prepare.
Editor's Page
Innovation Insight
25 Years On, OCT Looks To Future
Co-inventor David Huang, PhD, shares the next big thing for today’s big thing.
News
North of the Border
MIVS and Post-op Endophthalmitis
A look at evolving trends and techniques.
Retina CEO
Benchmarking Tool Can Track Coding
Retina PractiCare tool can show how your claims compare with peers’—and maybe help keep auditors away.
Retina Fellows Forum
Next-Generation Therapies For Wet AMD: Upgrade 2.0
Making the case for combination therapies.
Retina Rounds
Managing High-Risk Asymptomatic RRD
Navigating a management dilemma in this young surgeon who had LASIK.
Surgical Pearl Video
A Novel Approach for Surgical PVD
This hydrodissection approach avoids risks of iatrogenic retinal tears and optic nerve traction.
Current Issue
Continuing Medical Education
Additional Publications
Tuesday, October 8, 2024 | Learn More About Stargardt Disease
Location: Webinar
Time: 7:00 PM ET
Time: 7:00 PM ET
Speaker: Lejla Vajzovic, MD, FASRS
Sponsored by Alkeus Pharmaceuticals, Inc.
Earlier Treatment Can Matter for Macular Edema Following Retinal Vein Occlusion
Treating Chronic Inflammation Associated With Uveitis Affecting the Posterior Segment in a Retina Setting with YUTIQ
GA: Recognizing the Burden
Treatment of Proliferative Diabetic Retinopathy
Improving Wet AMD Outcomes With a Fellow Eye Strategy
